Search
On May 20, 2026, a momentous event unfolded in Guangzhou as Guangzhou Pharmaceutical Group, Huawei, and Wangshi AI joined hands to sign an AI-driven pharmaceutical ecological cooperation agreement. In the context of its digital and intelligent transformation journey, Guangzhou Pharmaceutical Group has zeroed in on AI-powered drug research and development as a pivotal area of focus. Huawei, renowned for its prowess in computing power, cloud technology, AI, and other cutting-edge domains, brings a wealth of expertise to the table. Meanwhile, Wangshi AI boasts specialized capabilities in AI-based small-molecule drug research. By pooling their respective core strengths, the trio aims to collectively construct an independently innovative AI drug design platform, thereby propelling the digital and intelligent evolution of pharmaceutical R&D to new heights.
-
C114 Communication Network -
Communication Home
